37 results
Thumbnail

D1.151 - Changes in Treatment Steps After Biological Therapy in Patients with Severe Asthma: Real-World Data

Thumbnail

D1.139 - Dupilumab was Effective in Black and Non-Black Patients with Asthma Completing 1 Year of the RAPID Registry

Thumbnail

D1.140 - Beyond Severe Asthma: Eosinophilic Granulomatosis with Polyangiitis Unmasked by Acute Myopericarditis

Thumbnail

D1.141 - Added value of impulse oscillometry in the early detection of small airway dysfunction in asthma

Thumbnail

D1.142 - Clinical remission in long-term biological therapy of severe asthma

Thumbnail

D1.143 - Clinical Efficacy of Biologics and ATAD in NSAID-Exacerbated Respiratory Disease: A Phenotype-Based Comparative Study

Thumbnail

D1.144 - Eosinophilic myocarditis as a complication of dupilumab treatment

Thumbnail

D1.145 - Clinical Impact of Type 2 Phenotype in Severe Asthma Patients with Exacerbations During Biologic Treatment

Thumbnail

D1.146 - Improved nocturnal oxygenation in a severe allergic asthma patient with comorbid sleep apnea under anti-TSLP biologic therapy

Thumbnail

D1.147 - Efficacy of benralizumab in Chinese patients with severe eosinophilic asthma: subgroup analysis of the 16-week results from STEP, a phase IIIb study of step-down maintenance therapy

Thumbnail

D1.148 - Real-world effectiveness of dupilumab administered every 4 weeks in patients with moderate to severe asthma

Thumbnail

D1.149 - Healthcare Professionals Typically Apply Higher Blood Eosinophil Count Thresholds for Biologic Selection Versus Clinical Guidelines in Severe Asthma

Thumbnail

D1.150 - Patient characteristics and treatment patterns in adults with severe asthma in Poland (POLSAR): a retrospective, single-center real-world cohort from ISAR

Thumbnail

D1.152 - Treatment-induced remission after mepolizumab discontinuation: case series

Thumbnail

D1.153 - Indirect Comparison of Biological Agents in Severe Asthma: Real-World Data

Thumbnail

D2.216 - Effectiveness and safety of subcutaneous immunotherapy with Depigmented-Polymerized Cat Extract: real-world clinical evidence

Thumbnail

D2.217 - Structured Follow-Up Intervals Enhance Adherence to Sublingual Immunotherapy in Patients with Allergic Rhinitis: Real-World Evidence from a Stepwise Approach

Thumbnail

D2.218 - Effectiveness of the 300IR house dust mite sublingual tablet according to the patients’ sensitisation and allergy profile in the real-world, non-interventional VORAN study

Thumbnail

D2.219 - Effectiveness of the 300IR house dust mite sublingual tablet in the real-world, non-interventional VORAN study: a responder analysis

Thumbnail

D2.222 - A real-world observational study following the first year of SQ grass or SQ tree SLIT-tablet treatment to evaluate persistence and adherence in routine clinical practice among general practitioners in Norway